r/IBRX

With no news of FDA decision in the 60-day window, is it safe to assume this was a Class 2 submission with a decision for Sep 2026?

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

For anyone worried about the price action of $IBRX these past few trading days:
- 4 analysts rate this as a buy or strong buy. All have maintained or raised their price targets. No holds, no sells.
- 50 MA for the 4 hour chart is about to cross over the 200 MA. Last time that happened was January when we saw a massive run-up.
- WeBull has a bullish technical outlook for the short, medium and longterm, with 8 recent bullish short term technical signals
- AUA conference is this weekend, coming off Dr. PSS's recent trip around the world, visiting world renowned labs, meeting with heads of state, and crafting deals yet to be announced to expand Anktiva's market share
- Makary was just forced out
- IB is working on AI automated robots to scale up production of Anktiva and expand into AI medicine

And much, much more. Stay bullish.

This could be huge news if the results are positive.

Simon Khagi is the principal investigator on ImmunityBio’s recurrent/progressive glioblastoma trial involving ANKTIVA / N-803, PD-L1 t-haNK NK-cell therapy, and bevacizumab, with some arms involving TTFields / Optune Gio. The NCI trial listing says the trial is active and describes a phase 2 plus phase 2B design for recurrent or progressive glioblastoma.

The big update is from January 23, 2026: ImmunityBio reported that in its phase 2 recurrent GBM data, median overall survival had not yet been reached. OncLive summarized that this was in the efficacy-evaluable group of 14 patients, with 19 of 23 total enrolled patients alive at the data cutoff, at a median follow-up of about 6 months.

Khagi’s quoted interpretation was notably strong: he said recurrent GBM typically has median overall survival of about 6 to 9 months, and that seeing durable responses and manageable safety without chemotherapy could represent a “paradigm change.” That said, these are still early, small-sample, not-yet-definitive clinical data, not proof of a cure.

Looks like the next real public numbers are likely May 21, 2026, or during ASCO May 29 to June 2, 2026 with Simon Khagi as first author/presenter for ANKTIVA / NAI plus PD-L1 t-haNK and bevacizumab in glioblastoma.

ASCO says the majority of abstracts are released May 21, 2026 at 5:00 PM ET, and the annual meeting runs May 29 to June 2, 2026 in Chicago. So the abstract may show updated numbers on May 21, with fuller poster/presentation details during the meeting.

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

https://x.com/i/status/2054241160302838219

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This is really big , it can not be priced under 50$ at least 150$..

The $7.76 support is ironclad ( I hope so xd ): short sellers are officially out of resources and under pressure.

Reported losses are secondary;. Stay patient,
trust the math, and wait for the market to correct. We hold the advantage!

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead!